Molecular Insights Into Post-Cardiac Arrest Brain Injury Via CSF Multi-Omics
PCABI-OMICS
Identification of Novel Molecular Pathophysiological Mechanisms of Secondary Brain Injury in Post-cardiac Arrest Syndrome Patients Using Cerebrospinal Fluid Multi-omics Analysis
2 other identifiers
observational
60
1 country
1
Brief Summary
The goal of this study is to uncover the molecular mechanisms responsible for secondary brain injury in patients with post-cardiac arrest syndrome by analyzing cerebrospinal fluid (CSF) using multi-omics techniques. The main question this study aims to answer is: Which genome-, transcriptome-, proteome-, and metabolome-level changes in CSF are associated with secondary brain injury after cardiac arrest? To address this question, CSF samples collected from post-cardiac arrest patients will undergo multi-omics analyses. Identified molecular pathways will be used to screen existing drug databases and generate new therapeutic candidates through computational modeling and compound synthesis. These findings will provide the scientific foundation needed to design and implement future preclinical experiments using cardiac arrest animal models.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Dec 2025
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 27, 2025
CompletedStudy Start
First participant enrolled
December 1, 2025
CompletedFirst Posted
Study publicly available on registry
March 18, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 30, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
February 28, 2028
March 18, 2026
March 1, 2026
2 years
November 27, 2025
March 16, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Neurological outcome
Neurological outcome assessed using the Cerebral Performance Category (CPC) scale (range 1-5; lower scores indicate better neurological function).
at discharge (assessed up to 3 days), 3 months after return of spontaneous circulation (ROSC)
Study Arms (2)
Favorable neurological outcome
The favorable neurological outcome group is classified as patients with a CPC score of 1 or 2 upon long-term follow-up (at discharge, 3 months after post-resuscitation)
Unfavorable neurological outcome
The favorable neurological outcome group is classified as patients with a CPC score of 3 to 5 upon long-term follow-up (at discharge, 3 months after post-resuscitation)
Eligibility Criteria
The study population for this research consists of a highly specific and clinically critical group of patients: Adults who have experienced out-of-hospital or in-hospital cardiac arrest and successfully regained spontaneous circulation (ROSC), but remain at high risk for secondary brain injury.
You may qualify if:
- Patients receiving post-resuscitation care after out-of-hospital cardiac arrest for secondary brain injury treatment.
- Patients without contraindications for lumbar puncture catheter insertion for cerebrospinal fluid (CSF) collection. This includes the absence of:
- Uncontrolled diabetes.Coagulation disorders.
- Thrombocytopenia (platelet count $\< 100,000).
- A history of cirrhosis diagnosis.
- Current receipt of low molecular weight heparin.
- Current use of platelet inhibitors.
- A history of posterior spinal fusion that may interfere with catheter insertion.
- Local skin infection or rash at the puncture site.
- Signs of systemic infection or sepsis.
- A history of lumbar puncture within the past 6 hours.
You may not qualify if:
- Cerebral Edema: Patients with evidence of cerebral edema on a brain computed tomography (CT) scan performed immediately after spontaneous circulation recovery.
- Patients who underwent extracorporeal membrane oxygenation (ECMO).
- Patients who could not maintain integrated therapy for more than 24 hours after cardiac arrest.
- Patients with a history of acute or chronic brain disease.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Chungnam National University Hospital
Daejeon, Jung-gu, 35015, South Korea
Related Publications (4)
5. Edgren E, Enblad P, Grenvik A, et al. Cerebral blood flow and metabolism after cardiopulmonary resuscitation. A pathophysiologic and prognostic positron emission tomography pilot study. Resuscitation 2003;57:161-70.
BACKGROUND4. Buunk G, van der Hoeven JG, Meinders AE. Cerebral blood flow after cardiac arrest. Neth J Med 2000;57:106-12.
BACKGROUNDMadl C, Holzer M. Brain function after resuscitation from cardiac arrest. Curr Opin Crit Care. 2004 Jun;10(3):213-7. doi: 10.1097/01.ccx.0000127542.32890.fa.
PMID: 15166839BACKGROUND1. Wiklund LM, Miclescu A, Semenas E, Rubertsson S, Sharma HS. Central nervoustissue damage after hypoxia and reperfusion in conjunction with cardiac arrest and cardiopulmonary resuscitation: mechanisms of action and possibilities for mitigation. Int Rev Neruobiol 2012;102:173-87.
BACKGROUND
Biospecimen
The primary and exclusive biological sample collected and retained for the multi-omics analysis is the cerebrospinal fluid and serum.
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 3 Months
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant professor
Study Record Dates
First Submitted
November 27, 2025
First Posted
March 18, 2026
Study Start
December 1, 2025
Primary Completion (Estimated)
November 30, 2027
Study Completion (Estimated)
February 28, 2028
Last Updated
March 18, 2026
Record last verified: 2026-03